<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826354</url>
  </required_header>
  <id_info>
    <org_study_id>SaveSAMS</org_study_id>
    <nct_id>NCT04826354</nct_id>
  </id_info>
  <brief_title>Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease</brief_title>
  <official_title>Effects of High-dose StAtin Versus Low-dose Statin Plus Ezetimibe on Statin-Associated Muscle Symptoms &amp; on Reaching Target LDL-C Levels Among Elderly Patients With Atherosclerotic Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-dose statins can reduce mortality and cardiovascular events in patients with established&#xD;
      atherosclerotic cardiovascular disease (ASCVD). Therefore, US and European recommendations&#xD;
      recommend that established ASCVD patients (coronary artery disease, cerebrovascular disease,&#xD;
      peripheral vascular disease) use high-dose statins to lower LDL cholesterol levels by at&#xD;
      least 50%. However, in actual practice, high-dose statins are relatively less used, and the&#xD;
      reason is unclear, but it is believed to be due to concerns about the side effects of&#xD;
      high-dose statins. Most of the side effects of statins are statin-associated muscle symptoms&#xD;
      (SAMS), which are more common than the incidence in clinical studies, especially in frontline&#xD;
      care. These muscle side effects are dose-dependent and are common at high doses, and the&#xD;
      incidence is known to increase in the elderly over 70 years of age. However, the US&#xD;
      recommendation recommends using high-dose statins to lower LDL cholesterol by 50% or more to&#xD;
      prevent cardiovascular events even in ASCVD patients over 70 years of age.&#xD;
&#xD;
      Most early studies on lowering LDL cholesterol in ASCVD patients used high doses of statins.&#xD;
      However, after introducing cholesterol absorption inhibitors ezetimibe and PCSK9 inhibitor,&#xD;
      large-scale clinical studies have been conducted to lower LDL cholesterol using these drugs.&#xD;
      In this study, as in the statin study, cardiovascular events were significantly reduced, and&#xD;
      together with statins, it became a standard treatment for ASCVD patients. On the other hand,&#xD;
      the clinical benefit shown in clinical studies using cholesterol-lowering agents so far&#xD;
      depends entirely on how much LDL cholesterol is lowered and how long it is maintained in a&#xD;
      low state, indicating that LDL cholesterol management is the core of arteriosclerosis&#xD;
      treatment. In addition to high-dose statins, a combination of low-dose statins and ezetimibe&#xD;
      can be cited as a method for lowering LDL cholesterol to more than 50%. In the latter case,&#xD;
      it is expected that there will be an advantage of reducing muscle side effects by reaching&#xD;
      the target LDL cholesterol level by using a low-dose statin. However, no studies compare the&#xD;
      difference in muscle side effects between low-dose statins and ezetimibe combination drugs,&#xD;
      which reduce LDL cholesterol to the same extent compared to high-dose statins, in elderly&#xD;
      patients over 70 years of age with ASCVD. In this study, the association of low-dose&#xD;
      rosuvastatin 5mg and ezetimibe combination (rosuvastatin 10/5mg) compared to high-dose&#xD;
      rosuvastatin 20mg in elderly patients 70 years of age or older with established ASCVD. This&#xD;
      study aims to compare and analyze the incidence of muscle symptoms (SAMS) and their effect on&#xD;
      LDL cholesterol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Established Atherosclerotic Cardiovascular Disease (ASCVD)&#xD;
&#xD;
      A. Coronary artery disease meeting at least one of the following criteria:&#xD;
&#xD;
        -  A history of coronary recanalization in multivessel coronary artery disease, evidenced&#xD;
           by any of the following:&#xD;
&#xD;
             1. Percutaneous coronary intervention (PCI) of one or more vessels, including&#xD;
                branching arteries&#xD;
&#xD;
             2. PCI or coronary artery bypass grafting (CABG) for &gt;50% residual stenosis in&#xD;
                separate vessels that have not undergone recanalization&#xD;
&#xD;
             3. multivessel CABG at least 5 years prior to screening&#xD;
&#xD;
        -  Significant coronary without prior revascularization, evidenced by &gt;70% stenosis in at&#xD;
           least one coronary artery, &gt;50% stenosis in two or more coronary arteries, or &gt;50%&#xD;
           stenosis in the left main coronary artery arterial disease&#xD;
&#xD;
        -  Known coronary calcium score &gt; 100 in subjects who did not undergo coronary&#xD;
           recanalization prior to randomization&#xD;
&#xD;
      B. Cerebrovascular Disease meeting at least one of the following criteria:&#xD;
&#xD;
        -  Previous transient ischemic attack with carotid artery stenosis in 50%&#xD;
&#xD;
        -  70% internal or external carotid artery stenosis or &gt;50% stenosis of two or more&#xD;
&#xD;
        -  Past history of recanalization of internal or external carotid artery&#xD;
&#xD;
      C. Peripheral arterial disease meeting at least one of the following criteria:&#xD;
&#xD;
        -  &gt; 50% stenosis in the arteries of the extremities&#xD;
&#xD;
        -  History of abdominal aortic treatment (percutaneous or surgical) for atherosclerotic&#xD;
           disease&#xD;
&#xD;
        -  Ankle Brachial Index (ABI) â‰¤ 0.90&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Effects of high-dose Statin Versus low-dose statin plus ezetimibe on statin-associated Muscle Symptoms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Statin-Associated Muscle Symptoms (SAMS)</measure>
    <time_frame>6 month</time_frame>
    <description>Patients with a Proposed Statin Myalgia Index score of 7 or higher (Cardiovasc Drugs Ther 2003;17:459-465):&#xD;
Aspects: muscle pain, muscle spasms, muscle stiffness, feeling of strength, ligament pain, etc.&#xD;
Location: thigh, buttocks, calves, back muscle, proximal arms&#xD;
Onset time after dosing: within 6 months&#xD;
Deteriorating factors: exercise, rest, cold exposure, position change, fasting&#xD;
Severe: Occurs in abnormalities in daily life, occurs in daily life, occurs in less than daily life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Target Low density lipoprotein cholesterol (LDL-C) achievement</measure>
    <time_frame>6 month</time_frame>
    <description>Target LDL-C achievement (LDL &lt;70mg/dL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CK levels</measure>
    <time_frame>6 month</time_frame>
    <description>Creatinine Kinase levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GOT levels</measure>
    <time_frame>6 month</time_frame>
    <description>Aspartate Transaminase (Glutamic Oxaloacetic Transaminase levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GPT levels</measure>
    <time_frame>6 month</time_frame>
    <description>Alanine Transaminase (Glutamic Pyruvic Transaminase) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Total cholesterol, LDL cholesterol, HDL cholesterol</measure>
    <time_frame>6 month</time_frame>
    <description>Levels of Total cholesterol, LDL cholesterol, HDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Triglyceride</measure>
    <time_frame>6 month</time_frame>
    <description>Level of Triglyceride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of high sensitive-CRP</measure>
    <time_frame>6 month</time_frame>
    <description>Level of high sensitive-CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of myopathy, rhabdomyolysis</measure>
    <time_frame>6 month</time_frame>
    <description>Incidence of myopathy, rhabdomyolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of drug discontinuation due to SAMS side effects</measure>
    <time_frame>6 month</time_frame>
    <description>Frequency of drug discontinuation due to SAMS side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of drug discontinuation due to side effects other than SAMS</measure>
    <time_frame>6 month</time_frame>
    <description>Frequency of drug discontinuation due to side effects other than SAMS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">582</enrollment>
  <condition>Atheroscleroses, Coronary</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvamibe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin plus ezetimibe 10/5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin and Ezetimibe</intervention_name>
    <description>Rosuvastatin Versus Rosuvastatin plus Ezetimibe</description>
    <arm_group_label>Rosuvamibe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (must satisfy all of the following selection criteria) :&#xD;
&#xD;
          1. Those who are 70 years of age or older as of the date of consent&#xD;
&#xD;
          2. Established arteriosclerotic cardiovascular disease (coronary artery disease,&#xD;
             cerebrovascular disease, or peripheral vascular disease)&#xD;
&#xD;
          3. Subjects who have consented to the study plan and follow-up observation by the patient&#xD;
             or representative, and who consented in advance in writing to the clinical subject&#xD;
             consent approved by the research deliberation committee/ethics committee of the&#xD;
             research institution&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Take statins or ezetimibe within the last 4 weeks&#xD;
&#xD;
          2. In case of end-stage kidney disease (eGFR&lt;30 ml/min/1.73m2)&#xD;
&#xD;
          3. Heart surgery or major surgery is planned within the next 6 months&#xD;
&#xD;
          4. Patients with chronic diseases such as severe lung disease, stroke, etc.&#xD;
&#xD;
          5. Patients with chronic inflammatory diseases who require oral, intravenous, or&#xD;
             intra-articular steroid treatment (Ointments, inhalants, or intranasal steroids are&#xD;
             allowed)&#xD;
&#xD;
          6. If you have been diagnosed with cancer within the past 1 year or are currently&#xD;
             receiving chemotherapy&#xD;
&#xD;
          7. In the case of clinically significant abnormal findings that may infringe on the&#xD;
             safety of the study by the investigator's judgment confirmed in a screening visit,&#xD;
             physical examination, blood test, or electrocardiogram&#xD;
&#xD;
          8. Liver disease, bile duct obstruction, or liver enzyme level (ALT/AST) is more than 3&#xD;
             times normal&#xD;
&#xD;
          9. If you have a disease whose life expectancy is less than 1 year&#xD;
&#xD;
         10. If you do not want or cannot comply with the procedure described in the research&#xD;
             proposal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78. Epub 2005 Sep 27. Erratum in: Lancet. 2005 Oct 15-21;366(9494):1358. Lancet. 2008 Jun 21;371(9630):2084.</citation>
    <PMID>16214597</PMID>
  </reference>
  <reference>
    <citation>Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, BorÃ©n J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, TokgÃ¶zoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144. Review.</citation>
    <PMID>28444290</PMID>
  </reference>
  <reference>
    <citation>Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.</citation>
    <PMID>21067804</PMID>
  </reference>
  <reference>
    <citation>Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):3168-3209. doi: 10.1016/j.jacc.2018.11.002. Epub 2018 Nov 10. Erratum in: J Am Coll Cardiol. 2019 Jun 25;73(24):3234-3237.</citation>
    <PMID>30423391</PMID>
  </reference>
  <reference>
    <citation>European Association for Cardiovascular Prevention &amp; Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093/eurheartj/ehr158. Epub 2011 Jun 28.</citation>
    <PMID>21712404</PMID>
  </reference>
  <reference>
    <citation>Pokharel Y, Tang F, Jones PG, Nambi V, Bittner VA, Hira RS, Nasir K, Chan PS, Maddox TM, Oetgen WJ, Heidenreich PA, Borden WB, Spertus JA, Petersen LA, Ballantyne CM, Virani SS. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide. JAMA Cardiol. 2017 Apr 1;2(4):361-369. doi: 10.1001/jamacardio.2016.5922.</citation>
    <PMID>28249067</PMID>
  </reference>
  <reference>
    <citation>Rodriguez F, Lin S, Maron DJ, Knowles JW, Virani SS, Heidenreich PA. Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines. Am Heart J. 2016 Dec;182:97-102. doi: 10.1016/j.ahj.2016.09.007. Epub 2016 Sep 29.</citation>
    <PMID>27914506</PMID>
  </reference>
  <reference>
    <citation>Rosenson RS, Kent ST, Brown TM, Farkouh ME, Levitan EB, Yun H, Sharma P, Safford MM, Kilgore M, Muntner P, Bittner V. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol. 2015 Jan 27;65(3):270-7. doi: 10.1016/j.jacc.2014.09.088.</citation>
    <PMID>25614424</PMID>
  </reference>
  <reference>
    <citation>Riphagen IJ, van der Veer E, Muskiet FA, DeJongste MJ. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin. 2012 Jul;28(7):1247-52. doi: 10.1185/03007995.2012.702102. Epub 2012 Jun 28.</citation>
    <PMID>22686958</PMID>
  </reference>
  <reference>
    <citation>Bruckert E, Hayem G, Dejager S, Yau C, BÃ©gaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005 Dec;19(6):403-14.</citation>
    <PMID>16453090</PMID>
  </reference>
  <reference>
    <citation>Armitage J. The safety of statins in clinical practice. Lancet. 2007 Nov 24;370(9601):1781-90. Review.</citation>
    <PMID>17559928</PMID>
  </reference>
  <reference>
    <citation>Nguyen KA, Li L, Lu D, Yazdanparast A, Wang L, Kreutz RP, Whipple EC, Schleyer TK. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Eur J Clin Pharmacol. 2018 Sep;74(9):1099-1109. doi: 10.1007/s00228-018-2482-9. Epub 2018 May 22. Review.</citation>
    <PMID>29785580</PMID>
  </reference>
  <reference>
    <citation>Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010 Jun;30(6):541-53. doi: 10.1592/phco.30.6.541.</citation>
    <PMID>20500044</PMID>
  </reference>
  <reference>
    <citation>Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin-associated myopathy. Int J Cardiol. 2012 Sep 6;159(3):169-76. doi: 10.1016/j.ijcard.2011.07.048. Epub 2011 Aug 2. Review.</citation>
    <PMID>21813193</PMID>
  </reference>
  <reference>
    <citation>Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.</citation>
    <PMID>26039521</PMID>
  </reference>
  <reference>
    <citation>Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.</citation>
    <PMID>28304224</PMID>
  </reference>
  <reference>
    <citation>Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7.</citation>
    <PMID>30403574</PMID>
  </reference>
  <reference>
    <citation>Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 Ã— 2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015 Apr 21;65(15):1552-61. doi: 10.1016/j.jacc.2015.02.020. Epub 2015 Mar 11.</citation>
    <PMID>25770315</PMID>
  </reference>
  <reference>
    <citation>Ference BA, Cannon CP, Landmesser U, LÃ¼scher TF, Catapano AL, Ray KK. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. Eur Heart J. 2018 Jul 14;39(27):2540-2545. doi: 10.1093/eurheartj/ehx450.</citation>
    <PMID>29020411</PMID>
  </reference>
  <reference>
    <citation>Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec AM. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012 Aug;223(2):251-61. doi: 10.1016/j.atherosclerosis.2012.02.016. Epub 2012 Feb 16. Review.</citation>
    <PMID>22410123</PMID>
  </reference>
  <reference>
    <citation>Yang YJ, Lee SH, Kim BS, Cho YK, Cho HJ, Cho KI, Kim SY, Ryu JK, Cho JM, Park JI, Park JS, Park CG, Chun WJ, Kim MA, Jin DK, Lee N, Kim BJ, Koh KK, Suh J, Lee SH, Lee BK, Oh SJ, Jin HY, Ahn Y, Lee SG, Bae JH, Park WJ, Lee SC, Lee HC, Lee J, Park C, Lee B, Jang Y. Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk. Clin Ther. 2017 Jan;39(1):107-117. doi: 10.1016/j.clinthera.2016.11.014. Epub 2016 Dec 19.</citation>
    <PMID>28007331</PMID>
  </reference>
  <reference>
    <citation>Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-e81. doi: 10.1161/ATV.0000000000000073. Review. Erratum in: Arterioscler Thromb Vasc Biol. 2019 May;39(5):e158.</citation>
    <PMID>30580575</PMID>
  </reference>
  <reference>
    <citation>Rosenson RS, Miller K, Bayliss M, Sanchez RJ, Baccara-Dinet MT, Chibedi-De-Roche D, Taylor B, Khan I, Manvelian G, White M, Jacobson TA. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability. Cardiovasc Drugs Ther. 2017 Apr;31(2):179-186. doi: 10.1007/s10557-017-6723-4.</citation>
    <PMID>28421332</PMID>
  </reference>
  <reference>
    <citation>Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, Chipkin S, Pescatello LS, Simpson K, White CM, Thompson PD. Effect of statins on skeletal muscle function. Circulation. 2013 Jan 1;127(1):96-103. doi: 10.1161/CIRCULATIONAHA.112.136101. Epub 2012 Nov 26.</citation>
    <PMID>23183941</PMID>
  </reference>
  <reference>
    <citation>Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, CeÅ¡ka R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA; GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19;315(15):1580-90. doi: 10.1001/jama.2016.3608.</citation>
    <PMID>27039291</PMID>
  </reference>
  <reference>
    <citation>Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013 Apr 2;158(7):526-34. doi: 10.7326/0003-4819-158-7-201304020-00004.</citation>
    <PMID>23546564</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Soon Jun Hong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Elderly</keyword>
  <keyword>Statin</keyword>
  <keyword>Ezetimibe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

